Clinical trials: Systemic Treatment
Early Onset Neonatal Sepsis
Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment
A prospective two-center antibiotic regimen switch study will be conducted to compare the clinical efficacy of two antibiotic regimens - penicillin/gentamicin versus ampicillin/gentamicin - in the empirical treatment of early…
- Trial name
- NCT00487019
- Where
- 2 sites in Estonia
- Volunteers
- 281 people
- Sponsor
- University of Tartu
COVID-19
INB03 for the Treatment of Pulmonary Complications From COVID-19
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
- Trial name
- NCT04370236
- Testing
- INB03
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- Inmune Bio, Inc.
Septic Shock, Hyperlactatemia
Early Goal Directed Therapy Using a Physiological Holistic View. The ANDROMEDA-SHOCK Study
Septic shock is a highly lethal condition associated with a mortality risk of 30 to 60%. Optimizing tissue perfusion and oxygenation is the aim to decrease mortality and morbidity in septic shock patients.
- Conditions
- Septic Shock, Hyperlactatemia, Peripheral Perfusion
- Trial name
- ANDROMEDA (NCT03078712)
- Testing
- Peripheral Perfusion guided resuscitation, Lactate guided resuscitation
- Where
- Chile
- Volunteers
- 424 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Neonatal SEPSIS, Very Low Birth Weight Baby
Efficacy of IgM Rich Immunoglobulin With Antibiotics for Bacterial Sepsis in Very Low Birth Weight Preterm Neonates
Study comprises of giving IVIG to half of the septic VLBW preterm neonates along with ongoing antibiotics and placebo to the other half. The immunoglobulin will be given for 3 days and neonates will be monitored for the results.
- Trial name
- IgMNS (NCT03403530)
- Testing
- IgM rich Immunoglobin
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Sir Takhtasinhji General Hospital
Early Diffuse Cutaneous Systemic Sclerosis
Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
The aim of the study is to compare the effectiveness of commonly used immunosuppressant treatments for early diffuse cutaneous systemic sclerosis (SSc).
- Trial name
- ESOS (NCT02339441)
- Testing
- Methotrexate, Mycophenolate mofetil, Cyclophosphamide
- Volunteers
- 320 people
- Sponsor
- University of Manchester
Periodontitis Stage IV, Periodontitis
Microbiological Modulation Of The Oral-Gut Axis After Treatment With Or Without Systemic Use Of Probiotics In Patients With Periodontitis: A Randomized Controlled Clinical Study.
This study aims to evaluate whether the oral administration of probiotics, in combination with conventional periodontal treatment (deep cleaning of the tooth root surfaces), can improve oral health and influence the relationship…
- Trial name
- NCT07792902
- Testing
- Probiotics Bifidobacterium animalis subsp. lactis HN019
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Hematologic Diseases, Sepsis
Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis
A SpetiFast multiplex PCR kit has recently been placed on the market witch can evidence the DNA of 90% of micro-organisms (bacteria and fungus) implicated in sepsis.
- Trial name
- SEPTIFAST (NCT00561639)
- Where
- France
- Volunteers
- 76 people
- Sponsor
- University Hospital, Grenoble
Breast Cancer, Neoadjuvant Therapy
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer
Today, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of controversy.
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Lymph Node Metastases
- Trial name
- MINIMAX (NCT04486495)
- Where
- 35 sites in Netherlands
- Volunteers
- 549 people
- Sponsor
- Maastricht University Medical Center
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
Retinopathy of Prematurity (ROP)
VEGF In Systemic Circulation Of ROP-infants
The purpose of this study is to measure systemic levels of vascular endothelial growth factor (VEGF) and other proteins (e.g. IGF-1) in the systemic circulation of infants with retinopathy of prematurity (ROP) following ocular…
- Trial name
- NCT01470430
- Where
- Germany
- Sponsor
- University Hospital Freiburg
Lupus Nephritis, Lupus Nephritis (LN)
Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of CD19 CAR-T cell therapy (TranspoCART19) in adults with refractory lupus nephritis.
- Trial name
- CART-NEL (NCT07799116)
- Testing
- TranspoCART19
- Where
- 8 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Haemophilus Infections
A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years
This will be an observational study where parents/ guardians of children in receipt of their preschool booster will be approached for their child(ren) to take part.
- Trial name
- DIPS (NCT00625118)
- Where
- 2 sites in United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Public Health England
Total Knee Arthroplasty
IO Vancomycin Administration in TKA
This is a prospective, single-center, open-label study evaluating systemic vancomycin levels following preoperative intraosseous administration in patients undergoing primary unilateral total knee arthroplasty.
- Trial name
- IO Vanco (NCT07633418)
- Testing
- Intraosseous Vamcomycin Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Hepatocellular Carcinoma (HCC), Metastasis
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
This study will evaluate whether resection of the primary liver tumor, in addition to standard first-line systemic therapy, improves survival in patients with hepatocellular carcinoma that has spread outside the liver but still…
- Trial name
- NCT07537959
- Testing
- Primary Tumor Resection, Protocol-Allowed First-Line Immune-Based Systemic Therapy
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Tongji Hospital
Sepsis
High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda
This feasibility study serves to determine if it is possible to perform a powered randomized control trial of high-dose intravenous vitamin C (ascorbic acid) as an adjunctive medication in the management of sepsis and septic…
- Trial name
- NCT04088591
- Testing
- Ascorbic Acid 500Mg/Ml Inj, Dextrose in Water
- Where
- Rwanda
- Sponsor
- Virginia Commonwealth University
Obstructive Jaundice
Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance
To explore the effects of pre-treatment with methylene blue on reduced perioperative vascular resistance in patients with obstructive jaundice.
- Trial name
- NCT03406676
- Testing
- Methylene Blue
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Southwest Hospital, China
Duchenne Muscular Dystrophy
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
This is a gene transfer therapy study evaluating the safety of delandistrogene moxeparvovec and delandistrogene moxeparvovec dystrophin expression in association with imlifidase, in participants with DMD with pre-existing…
- Trial name
- NCT06241950
- Testing
- delandistrogene moxeparvovec, imlifidase
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Sarepta Therapeutics, Inc.
Colorectal Neoplasms Malignant
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection is one of the primary treatment options for CRC; however, postoperative recurrence remains a significant clinical challenge for both the…
- Trial name
- NCT06778382
- Testing
- Oligometastasis Treatment
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shandong Cancer Hospital and Institute
SLE, SLE (Systemic Lupus)
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT06613360
- Testing
- CLN-978
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 24 people
- Sponsor
- Cullinan Therapeutics Inc.